You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLFA703
Accession NumberDB03932  (EXPT00387)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightAverage: 603.7881
Monoisotopic: 603.355988305
Chemical FormulaC37H49NO6
InChI KeyWPVRNXUYVXQXPY-UVJQNAMXSA-N
InChI
InChI=1S/C37H49NO6/c1-6-23(3)37(42)44-34-16-22(2)15-27-9-7-24(4)30(36(27)34)13-11-28-18-29(40)19-35(41)38(28)20-25-8-12-31-26(17-25)10-14-33(43-5)32(31)21-39/h7-10,12,14-15,17,22-24,28-30,34,36,39-40H,6,11,13,16,18-21H2,1-5H3/t22-,23-,24-,28-,29+,30-,34+,36-/m1/s1
IUPAC Name
(1S,3S,7R,8R,8aS)-8-{2-[(2R,4S)-4-hydroxy-1-{[5-(hydroxymethyl)-6-methoxynaphthalen-2-yl]methyl}-6-oxopiperidin-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2R)-2-methylbutanoate
SMILES
CC[C@@H](C)C(=O)O[[email protected]]1C[[email protected]](C)C=C2C=C[C@@H](C)[C@@H](CC[C@@H]3C[[email protected]](O)CC(=O)N3CC3=CC=C4C(C=CC(OC)=C4CO)=C3)[[email protected]]12
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Integrin alpha-LProteinunknownNot AvailableHumanP20701 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8102
Blood Brain Barrier+0.5485
Caco-2 permeable-0.5432
P-glycoprotein substrateSubstrate0.8663
P-glycoprotein inhibitor INon-inhibitor0.6283
P-glycoprotein inhibitor IIInhibitor0.5377
Renal organic cation transporterNon-inhibitor0.6871
CYP450 2C9 substrateNon-substrate0.851
CYP450 2D6 substrateNon-substrate0.8161
CYP450 3A4 substrateSubstrate0.7615
CYP450 1A2 substrateNon-inhibitor0.7023
CYP450 2C9 inhibitorNon-inhibitor0.8567
CYP450 2D6 inhibitorNon-inhibitor0.8536
CYP450 2C19 inhibitorNon-inhibitor0.7819
CYP450 3A4 inhibitorInhibitor0.6508
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7378
Ames testNon AMES toxic0.6601
CarcinogenicityNon-carcinogens0.9021
BiodegradationNot ready biodegradable0.5732
Rat acute toxicity2.7841 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8512
hERG inhibition (predictor II)Inhibitor0.5889
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00152 mg/mLALOGPS
logP5.51ALOGPS
logP5.19ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)14.62ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area96.3 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity174.37 m3·mol-1ChemAxon
Polarizability69.88 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassBenzylpiperidines
Direct ParentN-benzylpiperidines
Alternative Parents
Substituents
  • N-benzylpiperidine
  • Alkaloid or derivatives
  • Naphthalene
  • Coniine
  • Benzylamine
  • Anisole
  • Piperidinone
  • Fatty acid ester
  • Delta-lactam
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Secondary alcohol
  • Lactam
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes.
Gene Name:
ITGAL
Uniprot ID:
P20701
Molecular Weight:
128768.495 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23